|
Recent Therapeutic
Advances in the Management of Metastatic Bladder Cancer: Managed
Care Perspectives on Immunotherapy in the First Line Setting is a
three-part webinar series
A continuing medical
education activity sponsored by NAMCP and AAMCN
This webinar series will provide critical updates on the advances in
the management of Bladder Cancer
These are archives of live webinars held between January 27, 2021 to
February 3, 2021
If you participated in any of the live webinars, you are not
eligible
to claim credit from the archive of that webinar.
By clicking on each of the titles, you will be able to participate
in each part.
It is not required that you participate in all three or in order.
These activities are valid from March 1, 2021 – June 30, 2022
This
series is supported by an educational grant from
Pfizer
Audience:
This activity is intended for healthcare professionals practicing in managed
care environments.
Instructions for CME/NCPD: Complete the pre-test,
listen to the audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your internet
browser without completing the post test, you will have ONE more opportunity to
complete. A score of 70% must be achieved on the post test to receive continuing
education credits. If you do not pass the post test after two attempts, you will
not be eligible to try again. Once you complete the evaluation form and score
70% or higher on your post test, you will automatically be given your
certificate.
Description:
Bladder cancer, also known as urothelial carcinoma,
is the ninth leading cause of cancer death in the United States. According to
the American Cancer Society, there will be 80,470 new cases of bladder cancer
and 17,670 deaths in the United States in 2020. Before the advent of new
treatments in recent years, the basic management of this illness has remained
unchanged for decades. Long-term survival for people diagnosed with advanced
bladder cancer is poor, with approximately 5% of patients with metastatic
bladder cancer surviving for 5 years or more. As the role of the immune system
in oncogenesis and therapy has become clearer across cancer types, new
approaches emerged with important benefits in metastatic bladder cancer, which
led to the introduction of immune checkpoint inhibitors. However, when those
options fail, options are sparse to manage this difficult disease. Fortunately
for patients with metastatic bladder cancer, new agents, including antibody-drug
conjugates, have recently emerged for patients who have failed on immunotherapy
and chemotherapy. It is for this reason that medical directors, oncologists,
practicing physicians, nurse case managers and other healthcare professionals
must be educated on these emerging options and strategies for their
implementation into the treatment paradigm, which will ultimately improve
patient outcomes in the metastatic bladder cancer patient population.
While immunotherapy has revolutionized care for metastatic bladder cancer, it
doesn't work for everyone. Patients who progress with or fail immunotherapy will
need subsequent therapy, and there is limited data to guide treatment selection.
New data from late-stage clinical trials introduce emerging targeted agents with
great promise in improving outcomes for these patients. As these options have
recently become available and shown the ability to improve outcomes in patients
with this difficult to treat disease, it is imperative that physician medical
directors, oncologists, practicing physicians, nurse case managers and other
healthcare professionals are brought up to date regarding these novel
treatments, so that they can properly approve and select therapy based on
individual patient characteristics for improved clinical and economic outcomes. |